Phase III study of BiondVax's universal flu vaccine candidate M-001 does not meet primary endpoint Oct. 26, 2020
Phase III studies of a quadrivalent virus-like particle influenza vaccine manufactured in plants Oct. 23, 2020
Phase III data reported on Merck & Co.'s 15-valent pneumococcal conjugate vaccine V-114 Oct. 21, 2020
RSS